biomolecules

MDPI

Research Article

Schild analysis of the interaction between parthenolide and cocaine for their effects on planarian motility suggests an allosteric relationship.

Jyothi Kakuturu[1], Mary O'Brien[2], and Oné R. Pagán[3*]

[1]Department of Biology, West Chester University; Jyothi91@hotmail.com
Present position: Resident Physician, MedStar Health, Columbia, MD 21044

[2]Department of Biology, West Chester University; mobrien7898@gmail.com
Present position: Research Data Management Specialist, Department of Public Health Sciences, Penn State College of Medicine.

[3]Department of Biology, West Chester University; opagan@wcupa.edu

**Corresponding author*
Department of Biology, West Chester University
750 S. Church St., West Chester, PA 19383-2112
Tel.: (610-346-2165).
https://orcid.org/0000-0001-8232-7346

Abstract: Freshwater planarians are an emerging animal model in neuropharmacology due to the parallels of their nervous system with the nervous system of vertebrates. Cocaine is a naturally occurring abused drug and the "founding member" of the local anesthetic family. Sesquiterpene lactones of the parthenolide class are naturally occurring products that act as behavioral and physiological antagonists of cocaine in planarians and rats, respectively. One of the best-characterized planarian behaviors induced by various compounds is the change in locomotor velocity. Previous work from our laboratory showed that both parthenolide and cocaine reduced planarian motility and that parthenolide reversed the cocaine-induced motility decrease at concentrations where parthenolide does not affect the movement of the worms. However, the exact mechanism of the cocaine/parthenolide antagonism in planarians is unknown. Here, we report the results of a Schild analysis to explore the parthenolide/cocaine relationship in the planarian *Girardia tigrina*. The Schild slopes of the Δ parthenolide ± cocaine and Δ cocaine ± parthenolide were -0.33 and -0.43, respectively. Neither slope was statistically different from -1, suggesting an allosteric relationship between these two

compounds. To our knowledge, this is the first study aimed at determining the mechanism of action of the antagonism between cocaine and parthenolide.

Keywords: planaria; cocaine; parthenolide; motility; Schild analysis; allosteric; orthosteric

1. Introduction

Freshwater planarians have a distinguished history in regenerative and developmental biology research; the study of these organisms in this context has been ongoing for more than two centuries and is still a source of profound insights in these areas, particularly since the availability of molecular biology, genomics, and bioinformatics tools and techniques [1-7]. More recently, planarians have emerged as a powerful model to study regenerative processes at the molecular level, specifically in nervous tissue (reviewed in [8-12]). Planarians are also an emerging pharmacological model system for three main reasons: (1) the varied behavioral responses that these organisms exhibit upon exposure to exogenous substances, responses closely reminiscent of vertebrate responses to drugs, (2) the similarities of their nervous system to the nervous system of vertebrates in terms of cellular biology and morphology, and (3) the presence of vertebrate-like neurotransmitter systems in these organisms ([13-17]. An especially active area of pharmacological research using planarians is *in vivo* study of the effect of abused drugs, including cocaine, amphetamines, ethanol, and nicotine, among others, to explore the effect of abused drugs in terms of acute exposure (toxicity) or sub-lethal concentrations that may lead to phenomena like desensitization and tolerance, as well as withdrawal-like behaviors [18-29]. Thus, planarians are uniquely positioned to integrate the ostensibly separate disciplines of regeneration, neuroscience, and pharmacology [30,31].

Cocaine (Figure 1) is a plant-derived compound (mainly from plants of the *Erythroxylum* genus [32,33]) and is the parent compound of the local anesthetic superfamily, which primarily targets voltage-gated sodium channels on the surface of nerve cells [34]. Besides its local anesthetic properties, cocaine's main behavioral effect is through its interaction with neurotransmitter transporters, particularly the dopamine transporter [35]. The naturally occurring sesquiterpene lactone parthenolide (Figure 1) is mainly isolated from the feverfew plant (*Tanacetum parthenium,* [36,37]), a plant used in traditional medicine in various cultures. Parthenolide and other sesquiterpenoid lactones are currently in clinical trials for their antitumoral and anti-inflammatory properties [38-41] among other interesting biochemical effects However, parthenolide and related compounds are also known to cause contact dermatitis and genotoxic effects [42-44].

The logical thread that led us to the study of the interaction of cocaine and the sesquiterpene lactones of the parthenolide family and the initial use of planarians for these

purposes is reviewed in detail elsewhere [4,45]. Our research established that parthenolide is a behavioral antagonist of cocaine in the planarians system, capable of counteracting the effects of acute cocaine exposure, which mimic toxicity effects [46], as well as preventing the induction of withdrawal-like behaviors by cocaine, which mimic chronic administration [47]. We also determined the minimal structural determinants of the parthenolide-like molecules capable of antagonizing the motility decrease induced by cocaine [48]. Additionally, we established that parthenolide is a specific cocaine antagonist for another acute administration effect, the induction of seizure-like movements [49] through experiments in which parthenolide prevented the expression of cocaine-induced seizure-like behavior, but not similar behaviors induced by nicotine and amphetamines, among other drugs [50]. Furthermore, in collaboration with another research group, we found that parthenolide antagonized the inhibitory effect of cocaine on dopaminergic neuronal firing rate in the ventral tegmental area of rats, opening the door to the potential of parthenolide as a cocaine antagonist in vertebrates [51] validating the usefulness and vertebrate relevance of the planarian model. Although the molecular targets of cocaine in mammals are well-understood, very little is known about the mechanism of action and molecular nature of the cocaine target (s) in planarians.

In the present work, we explore the relationship between parthenolide and cocaine in terms of their effects on planarian motility using a Schild analysis to obtain information about the mechanism of this interaction.



Figure 1. Compounds tested in this work.

2. Materials and Methods

Brown planarians (*Girardia tigrina*) were purchased from Ward's (Rochester, NY). Parthenolide and cocaine were purchased from Tocris (Minneapolis, MN) and Sigma-Aldrich (St. Louis, MO), respectively. General laboratory materials, chemicals, and supplies were purchased from Fisher Scientific (Suwanee, GA). All graphs and statistical analyses were done with the Prism software package (GraphPad Inc., San Diego, CA). Upon arrival at our laboratory, the flatworms were transferred to artificial pond water (APW: 6 mM NaCl, 0.1 mM $NaHCO_3$, 0.6 mM $CaCl_2$) and were allowed to acclimate to laboratory conditions for at least 24 hours before using them for experiments. The worms

were used within three weeks of arrival. The APW was changed at least once every day except during weekends and immediately before any experiments.

All experiments were performed at room temperature in APW containing 0.1 % dimethylsulfoxide (DMSO) as a solubility-enhancing agent for parthenolide; this concentration of DMSO does not display any apparent behavioral or toxic effects in planarians [52].

We adapted a published protocol to measure planarian motility [53], as modified in [24,25,46,52,54]. Briefly, using a small paintbrush or plastic pipette, a planarian (1.0-1.5 cm long) was placed in a transparent, APW-rinsed, 6 cm polystyrene Petri dish; the dish was placed over a one cm^2 grid, and five milliliters of APW/0.1 % DMSO (control) or 5 mL of the experimental solutions in 0.1 % DMSO were added to the dish. The motility of the worm was measured by counting the squares crossed or recrossed per minute for 5 minutes. Each worm was used only once. The data was then plotted as cumulative crosses vs. time and fit using simple linear regression to obtain its slope. In experiments where the worms were exposed to various concentrations of the experimental compounds, the slopes obtained from the linear regression were normalized to control slopes (APW/0.1 % DMSO) and graphed as the fraction of control vs. the experimental compound concentration [24,25,46,52,54]. To analyze these concentration-response curves, we fit the data to an empirical Hill equation (Equation 1) in the form:

$$\mathbf{F = IC_{50}^{n} / (IC_{50}^{n} + [Compound]^{n})} \qquad \textit{Equation1}$$

F is the fraction of control, [Compound] is the experimental compound concentration in μM, IC_{50} is the compound concentration that decreased planarian motility by 50 %, and n is the Hill coefficient. The Hill coefficient is a parameter that can be used to estimate the kind and the degree of cooperativity in multimeric proteins. Although a useful parameter for the initial exploration of cooperativity, its direct link to the actual physical reality of a system is controversial [55,56]. In general, the usefulness of empirical models lies in the fact that they may provide helpful mechanistic insights and information about the pharmacology of a compound when little or no information exists about either the ligand or its putative target [57-59].

We performed two sets of experiments to observe the effect of parthenolide or cocaine on the IC_{50} of the other to decrease planarian motility: A series of concentration-response curves of cocaine in the absence or the presence of single concentrations of parthenolide (Δ cocaine ± parthenolide), and a series of concentration-response curves of parthenolide in the absence or the presence of single concentrations of cocaine (Δ parthenolide ± cocaine). In these experiments, the compound used in the concentration-response curve (the Δ compound) was defined as "Compound A," and the compound added at a single concentration was defined as "Compound B." The concentration of compound B was

chosen based on its inability to slow down the worms [50]. The shift in the IC_{50} for compound A, as induced by the single concentration of compound B, was subjected to Schild analysis by fitting the data to a linear equation (Equation 2) in the form:

$$\log (DR - 1) = S (-\log [B]) + b \qquad \textit{Equation 2}$$

The DR is the dose ratio, obtained by dividing the IC_{50} value obtained from a concentration-response curve of compound A in the presence and absence of compound B. S is the Schild Slope, and b is the y-intercept. A Schild Slope statistically equal to unity suggests an orthosteric relationship between the tested compounds; conversely, a Schild Slope statistically different from unity suggests an allosteric relationship between the tested compounds [60-65].

3. Results

3.1. Planarian motility decreases in response to the exposure of either parthenolide or cocaine. Figure 2 shows the concentration-response curves of cocaine or parthenolide for planarian motility. The IC_{50} values (421 and 93 μM for cocaine or parthenolide, respectively) are consistent with previous reports from our laboratory [50].



Figure 2. Parthenolide and cocaine decrease planarian motility in a concentration-dependent manner. Each data point represents the average of the responses of 6 worms. The lines were generated by fitting the data to Equation 1. The error bars represent the standard error of the mean. Symbols without visible error bars are bigger than the size of the SEM value.

3.2. Combination experiments. Figure 3 shows representative curve pairs of Δ parthenolide ± cocaine or of Δ cocaine ± parthenolide, showing the apparent IC_{50} shift of

the experimental compounds, as indicated. Pairs of curves for each of the conditions were obtained, and their parameters from the fit to either Equation 1 or Equation 2 are shown in Table 1.



Figure 3. Representative concentration-response curves of motility decrease by parthenolide or cocaine in the absence and the presence of a single concentration of the other, as indicated (see section 3.1 and Table 1). Each data point represents the average of the responses of 4 worms. The lines were generated by fitting que data to Equation 1. The error bars represent the standard error of the mean. The Hill and Schild parameters for all pairs are listed in Table 1.

Table 1. Hill and Schild parameters for the data fit to Equations 1 and 2 (see text).

Treatment	IC_{50} (μM ± SEM)	DR	log (DR-1)	B (Cocaine, μM)	-log B
Parthenolide (no Cocaine)	134.5 ± 18.7	-	-	-	
Parthenolide + 1 μM cocaine	159.8 ± 2.5	1.19	-0.72	1	0
Parthenolide (no Cocaine)	121.4 ± 16.8	-	-	-	
Parthenolide + 10 μM cocaine	231.7 ± 48.5	1.91	-0.04	10	1
Parthenolide (no Cocaine)	114.2 ± 5.4	-	-	-	
Parthenolide + 20 μM cocaine	256.8 ± 66.8	2.25	0.10	20	1.31

Parthenolide (no Cocaine)	89.1 ± 8.8	-	-	-	
Parthenolide + 50 μM cocaine	158.8 ± 7.5	1.78	-0.11	50	1.70
Treatment	**IC_{50} (μM ± SEM)**	**DR**	**log (DR-1)**	**B (Parthenolide, μM)**	**-log B**
Cocaine (no Parthenolide)	146.7 ± 17.4	-	-	-	
Cocaine + 1 μM Parthenolide	176.2 ± 24.7	1.20	-0.70	1	0
Cocaine (no Parthenolide)	303.3 ± 17.4	-	-	-	
Cocaine + 10 μM Parthenolide	404.5 ± 94.0	1.33	-0.48	10	1
Cocaine (no Parthenolide)	222.5 ± 19.7		-	-	
Parthenolide + 25 μM cocaine	363.4 ± 192.1	1.63	-0.20	25	1.40
Cocaine (no Parthenolide)	391.8 ± 111.9		-	-	
Cocaine + 50 μM Parthenolide	656.0 ± 150.5	1.67	-0.17	50	1.70

187



Figure 4. Parthenolide increases the apparent IC_{50} of cocaine and vice versa. The scatterplots of Δ parthenolide in the absence or in the presence of cocaine (at left) or Δ cocaine in the absence or in the presence of parthenolide (at right) show that for each treatment pair, the IC_{50} of the Δ compound increases with the presence of the second compound (see text). Error bars represent the standard error of the mean.

3.3. Schild analysis. Figure 4 shows Schild plots of the two tests we performed. For the Δ parthenolide ± cocaine or of Δ cocaine ± parthenolide the Schild slopes were -0.33 ± 0.06 and -0.43 ± 0.18, respectively. Both slopes were statistically different from -1 ($p = 0.002$ and 0.0498, respectively) and were not statistically different from each other ($p = 0.633$).



Figure 5. Schild Plots (abscissa and ordinate values from Table 1, see text). The Schild Slopes are not statistically different from each other (see text).

4. Discussion.

In this work, we provided a deeper analysis of the parthenolide and cocaine antagonism in the planarian system. The molecular targets of cocaine in vertebrates are well known (voltage-gated sodium channels and monoamine transporters), and its interaction with these targets accounts for virtually every observed effect of cocaine in biological systems. Planarians possess genes analogous to these proteins according to genomic data available in various databases [6,7,66,67], and all available evidence suggests that they function analogously in planaria as they do in vertebrates.

In contrast, the nature of the molecular target (s) of parthenolide and related sesquiterpene lactones is less clear; in fact, parthenolide has been described as having a "*…promiscuous bioactivity profile…*" [40]. Most studies on the molecular effects of parthenolide and related compounds focus on their impact on IkB kinases and nuclear factor kappa-B (NF-κB) and several classes of cytokines downstream of it, which may account for parthenolide's antitumoral and anti-inflammatory properties [68,69]. Additionally, parthenolide interferes with microtubule physiology [70,71] and, intriguingly, has been proposed as an agent that promotes functional nervous tissue regeneration [72], in contrast to results obtained from our laboratory (in preparation). Interestingly, "non-canonical" targets of cocaine include microtubules and microtubule-associated proteins [73-75]. At the time of writing, this is the only possible common target between cocaine and the sesquiterpene lactones, but further study is needed to ascertain whether this is the actual link between these two experimental compounds.

The fact that cocaine and parthenolide affect the apparent effect of the other suggests a mutually exclusive binding relationship between these compounds for their motility decrease properties in planarians, consistent with previous studies from our laboratory [46] (Figures 3 and 4). However, the exact nature of this relationship is unknown. The simplest interpretation of this data would be that parthenolide and cocaine display an orthosteric interaction (a single type of binding site shared by both compounds or, alternatively, separate yet overlapping binding sites). On the other hand, the parthenolide/cocaine interaction could be allosteric, where each compound would have its individual, non-overlapping (yet related to the other's) binding site. To distinguish between these two possibilities, we performed a Schild analysis [60-61] of the IC_{50} shift data from Table 1. Briefly, if the value of the Schild slope is statistically equal to unity, the data would suggest an orthosteric relationship between parthenolide and cocaine. On the other hand, if the slope is significantly different from unity, the data would suggest an allosteric relationship between the two compounds [59-65].

Our analysis found that Schild Slopes or parthenolide and cocaine were -0.33 ± 0.06 and -0.43 ± 0.18, respectively. Both slopes were statistically different from -1 ($p = 0.002$ and

0.0498, respectively) and were not statistically different from each other (p = 0.633), suggesting that parthenolide and cocaine are allosteric inhibitors of each other.

In planarians, cocaine induces other types of behaviors in addition to motility decrease. Some of these behaviors are expressed under acute exposure conditions, such as seizure-like hyperkinesia [26,27,31] (an effect that parthenolide also alleviates [50]), light/dark environmental preference (which is interpreted as anxiety-like responses [76,77]), and behavioral and cross-sensitization [78]. Also, chronic exposure to cocaine induces conditioned place preference behaviors [79] and even withdrawal-like behaviors [28,29] (another behavior that parthenolide does not induce [47]. Of these cocaine-induced behaviors, we have demonstrated that parthenolide and related analogs antagonize cocaine-induced motility decrease and seizure-like hyperkinesia [46,50], as well as withdrawal-like behaviors [47].

The study of these other cocaine-induced behaviors in planarians and their alleviation by sesquiterpene lactones of the parthenolide class will likely shed light on the mechanism of action of cocaine and perhaps other abused drugs. Such studies may include detailed mechanistic studies of cocaine-induced seizure-like hyperkinesia, light/dark preference, withdrawal-like behaviors, and habituation and desensitization—furthermore, structure-activity studies of cocaine alleviation by different sesquiterpene lactones of the parthenolide class may prove valuable. In fact, such a compound (costunolide, Figure 6) displays a higher potency for the alleviation of cocaine-induced motility decrease [46].

Any additional information that we obtain from these approaches has the potential to contribute to a better understanding of how cocaine and related compounds cause their harmful effects in vertebrates and will likely point to potential novel strategies to prevent such undesirable effects *in vivo*.



COSTUNOLIDE

Figure 6. Costunolide (see text).

Author Contributions: Conceptualization, J.K., M.O., O.R.P.; methodology, J.K., M.O., O.R.P.; formal analysis, ORP; investigation, J.K., M.O., O.R.P.; resources, O.R.P.; data curation, O.R.P.; writing—original draft preparation, J.K; writing—review and editing, O.R.P.; supervision, O.R.P.; project administration, O.R.P.; funding acquisition, O.R.P. All authors read and agreed to the published version of the manuscript.

Funding: Support from the National Institutes of Health (R03 DA026518 to ORP) is gratefully acknowledged. The NIH did not have any role in this report's study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in any process related to submitting this paper for publication.

Data Availability Statement: Available upon request.

Acknowledgments: We thank the Department of Biology and the College of Science and Mathematics, West Chester University, for institutional and financial support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Birkholz, T.R.; Van Huizen, A.V.; Beane, W.S. Staying in Shape: Planarians as a Model for Understanding Regenerative Morphology. *Seminars in Cell & Developmental Biology* **2019**, *87*, 105–115, doi:10.1016/j.semcdb.2018.04.014.

2. Baguñà, J. Planarian Regeneration between 1960s and 1990s: From Skilful Baffled Ancestors to Bold Integrative Descendants. A Personal Account. *Seminars in Cell & Developmental Biology* **2019**, *87*, 3–12, doi:10.1016/j.semcdb.2018.04.011.

3. Karami, A.; Tebyanian, H.; Goodarzi, V.; Shiri, S. Planarians: An In Vivo Model for Regenerative Medicine. *IJSC* **2015**, *8*, 128–133, doi:10.15283/ijsc.2015.8.2.128.

4. Pagán, O.R. *The First Brain: The Neuroscience of Planarians*; Oxford University Press: Oxford, 2014; ISBN 9780199965045.

5. Pellettieri, J. Regenerative Tissue Remodeling in Planarians – The Mysteries of Morphallaxis. *Seminars in Cell & Developmental Biology* **2019**, *87*, 13–21, doi:10.1016/j.semcdb.2018.04.004.

6. Robb, S.M.C.; Gotting, K.; Ross, E.; Sánchez Alvarado, A. SmedGD 2.0: The *Schmidtea mediterranea* Genome Database. *Genesis* **2015**, *53*, 535–546, doi:10.1002/dvg.22872.

7. Brandl, H.; Moon, H.; Vila-Farré, M.; Liu, S.-Y.; Henry, I.; Rink, J.C. PlanMine – a Mineable Resource of Planarian Biology and Biodiversity. *Nucleic Acids Res* **2016**, *44*, D764–D773, doi:10.1093/nar/gkv1148.

8. Cebrià, F. Regenerating the Central Nervous System: How Easy for Planarians! *Dev Genes Evol* **2007**, *217*, 733–748, doi:10.1007/s00427-007-0188-6.

9. Gentile, L.; Cebrià, F.; Bartscherer, K. The Planarian Flatworm: An in Vivo Model for Stem Cell Biology and Nervous System Regeneration. *Disease Models & Mechanisms* **2011**, *4*, 12–19, doi:10.1242/dmm.006692.

10. Owlarn, S.; Bartscherer, K. Go Ahead, Grow a Head! A Planarian's Guide to Anterior Regeneration: Planarian Anterior Regeneration. *Regeneration* **2016**, *3*, 139–155, doi:10.1002/reg2.56.

11. Ross, K.G.; Currie, K.W.; Pearson, B.J.; Zayas, R.M. Nervous System Development and Regeneration in Freshwater Planarians. *WIREs Developmental Biology* **2017**, *6*, e266, doi:10.1002/wdev.266.

12. Wyss, L.S.; Bray, S.R.; Wang, B. Cellular Diversity and Developmental Hierarchy in the Planarian Nervous System. *Current Opinion in Genetics & Development* **2022**, *76*, 101960, doi:10.1016/j.gde.2022.101960.

13. Sarnat, H.B.; Netsky, M.G. When Does a Ganglion Become a Brain? Evolutionary Origin of the Central Nervous System. *Seminars in Pediatric Neurology* **2002**, *9*, 240–253, doi:10.1053/spen.2002.32502.

14. Sarnat, H.B.; Netsky, M.G. The Brain of the Planarian as the Ancestor of the Human Brain. *Can. j. neurol. sci.* **1985**, *12*, 296–302, doi:10.1017/S031716710003537X.

15. Buttarelli, F.R.; Pellicano, C.; Pontieri, F.E. Neuropharmacology and Behavior in Planarians: Translations to Mammals. *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology* **2008**, *147*, 399–408, doi:10.1016/j.cbpc.2008.01.009.

16. Ribeiro, P.; El-Shehabi, F.; Patocka, N. Classical Transmitters and Their Receptors in Flatworms. *Parasitology* **2006**, *131*, S19, doi:10.1017/S0031182005008565.

17. Cebrià, F.; Kudome, T.; Nakazawa, M.; Mineta, K.; Ikeo, K.; Gojobori, T.; Agata, K. The Expression of Neural-Specific Genes Reveals the Structural and Molecular Complexity of the Planarian Central Nervous System. *Mechanisms of Development* **2002**, *116*, 199–204, doi:10.1016/S0925-4773(02)00134-X.

18. *Planaria: A Model for Drug Action and Abuse*; Raffa, R.B., Rawls, S.M., Eds.; Molecular biology intelligence unit; Landes Bioscience: Austin, Tex, 2008; ISBN 9781587063329.

19. Rawls, S.M.; Patil, T.; Tallarida, C.S.; Baron, S.; Kim, M.; Song, K.; Ward, S.; Raffa, R.B. Nicotine Behavioral Pharmacology: Clues from Planarians. *Drug and Alcohol Dependence* **2011**, *118*, 274–279, doi:10.1016/j.drugalcdep.2011.04.001.

20. Bach, D.J.; Tenaglia, M.; Baker, D.L.; Deats, S.; Montgomery, E.; Pagán, O.R. Cotinine Antagonizes the Behavioral Effects of Nicotine Exposure in the Planarian *Girardia tigrina*. *Neuroscience Letters* **2016**, *632*, 204–208, doi:10.1016/j.neulet.2016.09.005.

21. Raffa, R.B.; Baron, S.; Bhandal, J.S.; Brown, T.; Song, K.; Tallarida, C.S.; Rawls, S.M. Opioid Receptor Types Involved in the Development of Nicotine Physical Dependence in an Invertebrate (Planaria) Model. *Pharmacology Biochemistry and Behavior* **2013**, *112*, 9–14, doi:10.1016/j.pbb.2013.09.012.

22. Pagán, O.R.; Deats, S.; Baker, D.; Montgomery, E.; Wilk, G.; Tenaglia, M.; Semon, J. Planarians Require an Intact Brain to Behaviorally React to Cocaine, but Not to React to Nicotine. *Neuroscience* **2013**, *246*, 265–270, doi:10.1016/j.neuroscience.2013.05.010.

23. Sal, F.; Prados, J.; Urcelay, G.P. Nicotine Chronic Tolerance Development and Withdrawal in the Planaria (*Schmidtea mediterranea*). *Pharmacology Biochemistry and Behavior* **2021**, *200*, 173075, doi:10.1016/j.pbb.2020.173075.

24. Pagán, O.R.; Montgomery, E.; Deats, S.; Bach, D.; Baker, D. Evidence of Nicotine-Induced, Curare-Insensitive, Behavior in Planarians. *Neurochem Res* **2015**, *40*, 2087–2090, doi:10.1007/s11064-015-1512-6.

25. Pagán, O.R.; Rowlands, A.L.; Fattore, A.L.; Coudron, T.; Urban, K.R.; Bidja, A.H.; Eterović, V.A. A Cembranoid from Tobacco Prevents the Expression of Nicotine-Induced Withdrawal Behavior in Planarian Worms. *European Journal of Pharmacology* **2009**, *615*, 118–124, doi:10.1016/j.ejphar.2009.05.022.

26. Tallarida, C.S.; Egan, E.; Alejo, G.D.; Raffa, R.; Tallarida, R.J.; Rawls, S.M. Levamisole and Cocaine Synergism: A Prevalent Adulterant Enhances Cocaine's Action in Vivo. *Neuropharmacology* **2014**, *79*, 590–595, doi:10.1016/j.neuropharm.2014.01.002.

27. Tallarida, C.S.; Bires, K.; Avershal, J.; Tallarida, R.J.; Seo, S.; Rawls, S.M. Ethanol and Cocaine: Environmental Place Conditioning, Stereotypy, and Synergism in Planarians. *Alcohol* **2014**, *48*, 579–586, doi:10.1016/j.alcohol.2014.07.006.

28. Raffa, R.B.; Valdez, J.M. Cocaine Withdrawal in Planaria. *European Journal of Pharmacology* **2001**, *430*, 143–145, doi:10.1016/S0014-2999(01)01358-9.

29. Raffa, R.B.; Desai, P. Description and Quantification of Cocaine Withdrawal Signs in Planaria. *Brain Research* **2005**, *1032*, 200–202, doi:10.1016/j.brainres.2004.10.052.

30. Pagán, O.R. Planaria: An Animal Model That Integrates Development, Regeneration and Pharmacology. *Int. J. Dev. Biol.* **2017**, *61*, 519–529, doi:10.1387/ijdb.160328op.

31. Pagán, O.R.; Baker, D.L.; Deats, S.; O'Brien, M.; Dymond, R.; DeMichele, G. Measuring Functional Brain Recovery in Regenerating Planarians by Assessing the Behavioral Response to the Cholinergic Compound Cytisine. *Int. J. Dev. Biol.* **2020**, *64*, 445–452, doi:10.1387/ijdb.180145op.

32. Tsuchiya, H. Anesthetic Agents of Plant Origin: A Review of Phytochemicals with Anesthetic Activity. *Molecules* **2017**, *22*, 1369, doi:10.3390/molecules22081369.

33. Ruetsch, Y.A.; Böni, T.; Borgeat, A. From Cocaine to Ropivacaine: The History of Local Anesthetic Drugs. *Curr Top Med Chem* **2001**, *1*, 175–182, doi:10.2174/1568026013395335.

34. Körner, J.; Albani, S.; Sudha Bhagavath Eswaran, V.; Roehl, A.B.; Rossetti, G.; Lampert, A. Sodium Channels and Local Anesthetics—Old Friends with New Perspectives. *Front. Pharmacol.* **2022**, *13*, 837088, doi:10.3389/fphar.2022.837088.

35. Vaughan, R.A.; Foster, J.D. Mechanisms of Dopamine Transporter Regulation in Normal and Disease States. *Trends in Pharmacological Sciences* **2013**, *34*, 489–496, doi:10.1016/j.tips.2013.07.005.

36. Ghantous, A.; Sinjab, A.; Herceg, Z.; Darwiche, N. Parthenolide: From Plant Shoots to Cancer Roots. *Drug Discovery Today* **2013**, *18*, 894–905, doi:10.1016/j.drudis.2013.05.005.

37. Chadwick, M.; Trewin, H.; Gawthrop, F.; Wagstaff, C. Sesquiterpenoids Lactones: Benefits to Plants and People. *IJMS* **2013**, *14*, 12780–12805, doi:10.3390/ijms140612780.

38. Ghantous, A.; Gali-Muhtasib, H.; Vuorela, H.; Saliba, N.A.; Darwiche, N. What Made Sesquiterpene Lactones Reach Cancer Clinical Trials? *Drug Discovery Today* **2010**, *15*, 668–678, doi:10.1016/j.drudis.2010.06.002.

39. Mathema, V.B.; Koh, Y.-S.; Thakuri, B.C.; Sillanpää, M. Parthenolide, a Sesquiterpene Lactone, Expresses Multiple Anti-Cancer and Anti-Inflammatory Activities. *Inflammation* **2012**, *35*, 560–565, doi:10.1007/s10753-011-9346-0.

40. Freund, R.R.A.; Gobrecht, P.; Fischer, D.; Arndt, H.-D. Advances in Chemistry and Bioactivity of Parthenolide. *Nat. Prod. Rep.* **2020**, *37*, 541–565, doi:10.1039/C9NP00049F.

41. Liu, J.; Cui, M.; Wang, Y.; Wang, J. Trends in Parthenolide Research over the Past Two Decades: A Bibliometric Analysis. *Heliyon* **2023**, *9*, e17843, doi:10.1016/j.heliyon.2023.e17843.

42. Paulsen, E. The Sesquiterpene Lactone Mix: A Review of Past, Present and Future Aspects. *Contact Dermatitis* **2023**, *89*, 434–441, doi:10.1111/cod.14419.

43. Amorim, M.H.R.; Gil Da Costa, R.M.; Lopes, C.; Bastos, M.M.S.M. Sesquiterpene Lactones: Adverse Health Effects and Toxicity Mechanisms. *Critical Reviews in Toxicology* **2013**, *43*, 559–579, doi:10.3109/10408444.2013.813905.

44. Nanda, A.; Wasan, A. Allergic Contact Dermatitis to Parthenolide. *The Journal of Allergy and Clinical Immunology: In Practice* **2016**, *4*, 993–994, doi:10.1016/j.jaip.2016.04.001.

45. Pagán, O.R. *Synthetic Local Anesthetics as Alleviators of Cocaine Inhibition of the Human Dopamine Transporter.*; PhD Dissertation; Cornell University.

46. Pagán, O.R.; Rowlands, A.L.; Azam, M.; Urban, K.R.; Bidja, A.H.; Roy, D.M.; Feeney, R.B.; Afshari, L.K. Reversal of Cocaine-Induced Planarian Behavior by Parthenolide and Related Sesquiterpene Lactones. *Pharmacology Biochemistry and Behavior* **2008**, *89*, 160–170, doi:10.1016/j.pbb.2007.12.008.

47. Rowlands, A.L.; Pagán, O.R. Parthenolide Prevents the Expression of Cocaine-Induced Withdrawal Behavior in Planarians. *European Journal of Pharmacology* **2008**, *583*, 170–172, doi:10.1016/j.ejphar.2008.01.012.

48. Baker, D.; Deats, S.; Boor, P.; Pruitt, J.; Pagán, O.R. Minimal Structural Requirements of Alkyl γ-Lactones Capable of Antagonizing the Cocaine-Induced Motility Decrease in Planarians. *Pharmacology Biochemistry and Behavior* **2011**, *100*, 174–179, doi:10.1016/j.pbb.2011.08.013.

49. Rawls, S.M.; Thomas, T.; Adeola, M.; Patil, T.; Raymondi, N.; Poles, A.; Loo, M.; Raffa, R.B. Topiramate Antagonizes NMDA- and AMPA-Induced Seizure-like Activity in Planarians. *Pharmacology Biochemistry and Behavior* **2009**, *93*, 363–367, doi:10.1016/j.pbb.2009.05.005.

50. Pagán, O.R.; Baker, D.; Deats, S.; Montgomery, E.; Tenaglia, M.; Randolph, C.; Kotturu, D.; Tallarida, C.; Bach, D.; Wilk, G.; et al. Planarians in Pharmacology: Parthenolide Is a Specific Behavioral Antagonist of Cocaine in the Planarian *Girardia tigrina*. *Int. J. Dev. Biol.* **2012**, *56*, 193–196, doi:10.1387/ijdb.113486op.

51. Schwarz, D.; Bloom, D.; Castro, R.; Pagán, O.R.; Jiménez-Rivera, C.A. Parthenolide Blocks Cocaine's Effect on Spontaneous Firing Activity of Dopaminergic Neurons in the Ventral Tegmental Area. *Curr Neuropharmacol* **2011**, *9*, 17–20, doi:10.2174/157015911795017010.

52. Pagán, O.R.; Rowlands, A.L.; Urban, K.R. Toxicity and Behavioral Effects of Dimethylsulfoxide in Planaria. *Neuroscience Letters* **2006**, *407*, 274–278, doi:10.1016/j.neulet.2006.08.073.

53. Raffa, R.B.; Holland, L.J.; Schulingkamp, R.J. Quantitative Assessment of Dopamine D2 Antagonist Activity Using Invertebrate (Planaria) Locomotion as a Functional Endpoint. *Journal of Pharmacological and Toxicological Methods* **2001**, *45*, 223–226, doi:10.1016/S1056-8719(01)00152-6.

54. Pagán, O.R.; Coudron, T.; Kaneria, T. The Flatworm Planaria as a Toxicology and Behavioral Pharmacology Animal Model in Undergraduate Research Experiences. *J Undergrad Neurosci Educ* **2009**, *7*, A48-52.

55. Weiss, J.N. The Hill Equation Revisited: Uses and Misuses. *FASEB J* **1997**, *11*, 835–841.

56. Lavrinenko, I.A.; Vashanov, G.A.; Nechipurenko, Yu.D. New Interpretation of the Hill Coefficient. *BIOPHYSICS* **2022**, *67*, 171–174, doi:10.1134/S0006350922020142.

57. Gesztelyi, R.; Zsuga, J.; Kemeny-Beke, A.; Varga, B.; Juhasz, B.; Tosaki, A. The Hill Equation and the Origin of Quantitative Pharmacology. *Arch. Hist. Exact Sci.* **2012**, *66*, 427–438, doi:10.1007/s00407-012-0098-5.

58. Goutelle, S.; Maurin, M.; Rougier, F.; Barbaut, X.; Bourguignon, L.; Ducher, M.; Maire, P. The Hill Equation: A Review of Its Capabilities in Pharmacological Modelling. *Fundamental Clinical Pharma* **2008**, *22*, 633–648, doi:10.1111/j.1472-8206.2008.00633.x.

59. Wyllie, D.J.A.; Chen, P.E. Taking The Time To Study Competitive Antagonism. *British J Pharmacology* **2007**, *150*, 541–551, doi:10.1038/sj.bjp.0706997.

60. Arunlakshana, O.; Schild, H.O. SOME QUANTITATIVE USES OF DRUG ANTAGONISTS. *British Journal of Pharmacology and Chemotherapy* **1959**, *14*, 48–58, doi:10.1111/j.1476-5381.1959.tb00928.x.

61. Colquhoun, D. Why the Schild Method Is Better than Schild Realised. *Trends in Pharmacological Sciences* **2007**, *28*, 608–614, doi:10.1016/j.tips.2007.09.011.

62. Tallarida, R.J. Interactions between Drugs and Occupied Receptors. *Pharmacology & Therapeutics* **2007**, *113*, 197–209, doi:10.1016/j.pharmthera.2006.08.002.

63. Kenakin, T.P. The Schild Regression in the Process of Receptor Classification. *Can. J. Physiol. Pharmacol.* **1982**, *60*, 249–265, doi:10.1139/y82-036.

64. Tallarida, R.J.; Jacob, L.S. *The Dose—Response Relation in Pharmacology*; Springer US: New York, NY, 1979; ISBN 9781468462678.

65. Tallarida, R.J. *Drug Synergism and Dose-Effect Data Analysis*; Chapman & Hall/CRC: Boca Raton, 2000; ISBN 9781584880455.

66. Castillo-Lara, S.; Pascual-Carreras, E.; Abril, J.F. PlanExp: Intuitive Integration of Complex RNA-Seq Datasets with Planarian Omics Resources. *Bioinformatics* **2020**, *36*, 1889–1895, doi:10.1093/bioinformatics/btz802.

67. An, Y.; Kawaguchi, A.; Zhao, C.; Toyoda, A.; Sharifi-Zarchi, A.; Mousavi, S.A.; Bagherzadeh, R.; Inoue, T.; Ogino, H.; Fujiyama, A.; et al. Draft Genome of Dugesia Japonica Provides Insights into Conserved Regulatory Elements of the Brain Restriction Gene Nou-Darake in Planarians. *Zoological Lett* **2018**, *4*, 24, doi:10.1186/s40851-018-0102-2.

68. Wu, J.; Wang, X.; Hou, Y.; Gong, P. Bioactivities and the Structural Modification of Parthenolide: A Review. *Med Chem Res* **2024**, *33*, 221–238, doi:10.1007/s00044-023-03181-0.

69. Zhu, S.; Sun, P.; Bennett, S.; Charlesworth, O.; Tan, R.; Peng, X.; Gu, Q.; Kujan, O.; Xu, J. The Therapeutic Effect and Mechanism of Parthenolide in Skeletal Disease, Cancers, and Cytokine Storm. *Front. Pharmacol.* **2023**, *14*, 1111218, doi:10.3389/fphar.2023.1111218.

70. Hotta, T.; Haynes, S.E.; Blasius, T.L.; Gebbie, M.; Eberhardt, E.L.; Sept, D.; Cianfrocco, M.; Verhey, K.J.; Nesvizhskii, A.I.; Ohi, R. Parthenolide Destabilizes Microtubules by Covalently Modifying Tubulin. *Current Biology* **2021**, *31*, 900-907.e6, doi:10.1016/j.cub.2020.11.055.

71. Miglietta, A.; Bozzo, F.; Gabriel, L.; Bocca, C. Microtubule-Interfering Activity of Parthenolide. *Chemico-Biological Interactions* **2004**, *149*, 165–173, doi:10.1016/j.cbi.2004.07.005.

72. Leibinger, M.; Zeitler, C.; Paulat, M.; Gobrecht, P.; Hilla, A.; Andreadaki, A.; Guthoff, R.; Fischer, D. Inhibition of Microtubule Detyrosination by Parthenolide Facilitates Functional CNS Axon Regeneration. *eLife* **2023**, *12*, RP88279, doi:10.7554/eLife.88279.

73. Damuka, N.; Orr, M.; Czoty, P.W.; Weiner, J.L.; Martin, T.J.; Nader, M.A.; Bansode, A.H.; Liyana Pathirannahel, B.S.; Mintz, A.; Macauley, S.L.; et al. Effect of Ethanol and Cocaine on [11C]MPC-6827 Uptake in SH-SY5Y Cells. *Mol Biol Rep* **2021**, *48*, 3871–3876, doi:10.1007/s11033-021-06336-7.

74. Calipari, E.S.; Godino, A.; Salery, M.; Damez-Werno, D.M.; Cahill, M.E.; Werner, C.T.; Gancarz, A.M.; Peck, E.G.; Jlayer, Z.; Rabkin, J.; et al. Synaptic Microtubule-Associated Protein EB3 and SRC Phosphorylation Mediate Structural and Behavioral Adaptations During Withdrawal From Cocaine Self-Administration. *J. Neurosci.* **2019**, *39*, 5634–5646, doi:10.1523/JNEUROSCI.0024-19.2019.

75. Damuka, N.; Martin, T.J.; Bansode, A.H.; Krizan, I.; Martin, C.W.; Miller, M.; Whitlow, C.T.; Nader, M.A.; Solingapuram Sai, K.K. Initial Evaluations of the Microtubule-Based PET Radiotracer, [11C]MPC-6827 in a Rodent Model of Cocaine Abuse. *Front. Med.* **2022**, *9*, 817274, doi:10.3389/fmed.2022.817274.

76. Nayak, S.; Roberts, A.; Bires, K.; Tallarida, C.S.; Kim, E.; Wu, M.; Rawls, S.M. Benzodiazepine Inhibits Anxiogenic-like Response in Cocaine or Ethanol Withdrawn Planarians. *Behavioural Pharmacology* **2016**, *27*, 556–558, doi:10.1097/FBP.0000000000000236.

77. Zewde, A.M.; Yu, F.; Nayak, S.; Tallarida, C.; Reitz, A.B.; Kirby, L.G.; Rawls, S.M. PLDT (Planarian Light/Dark Test): An Invertebrate Assay to Quantify Defensive Responding and Study Anxiety-like Effects. *Journal of Neuroscience Methods* **2018**, *293*, 284–288, doi:10.1016/j.jneumeth.2017.10.010.

78. Rawls, S.M.; Patil, T.; Yuvasheva, E.; Raffa, R.B. First Evidence That Drugs of Abuse Produce Behavioral Sensitization and Cross Sensitization in Planarians. *Behavioural Pharmacology* **2010**, *21*, 301–313, doi:10.1097/FBP.0b013e32833b0098.

79. Hutchinson, C.V.; Prados, J.; Davidson, C. Persistent Conditioned Place Preference to Cocaine and Withdrawal Hypo-Locomotion to Mephedrone in the Flatworm Planaria. *Neuroscience Letters* **2015**, *593*, 19–23, doi:10.1016/j.neulet.2015.03.021.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.